CHPA Names Seven New Board Members and Taps Bayer’s David Tomasi as Chair-Elect

Why It Matters

Fresh leadership equips CHPA to steer a rapidly expanding self‑care market and influence regulatory policies that affect manufacturers and consumers alike.

Key Takeaways

• David Tomasi appointed CHPA chair‑elect, starts March 2027
• Seven new board members represent OTC, supplements, personal care
• Board turnover ensures fresh perspectives amid self‑care growth
• CHPA focuses on advocacy, regulatory engagement, industry collaboration
• Digital health and retail shifts drive consumer healthcare transformation

Pulse Analysis

The Consumer Healthcare Products Association (CHPA) has long served as the collective voice for manufacturers of over‑the‑counter medicines, dietary supplements, and medical devices. As the self‑care market expands—projected to exceed $200 billion globally by 2028—CHPA’s influence on policy, standards, and market access becomes increasingly pivotal. The association’s annual Self‑Care Leadership Summit, which convened more than 300 executives, underscored the sector’s rapid evolution, from traditional retail shelves to omnichannel distribution and digital health platforms. In this climate, strong governance is essential to steer industry priorities and maintain consumer trust.

The recent board refresh introduces seven executives from Vespyr, Let There Be, Perrigo, Designs for Health, Market Performance Group, Kenvue, and Klick, injecting expertise across OTC, nutraceuticals, and consumer‑services. Their appointment coincides with the selection of Bayer’s North America consumer‑health president, David Tomasi, as chair‑elect. Tomasi’s track record of scaling multinational brands and navigating complex regulatory landscapes equips CHPA to address emerging challenges such as label compliance, ingredient transparency, and cross‑border market entry. His upcoming chairmanship signals a strategic alignment between large‑scale pharma expertise and the association’s advocacy agenda.

Looking ahead, CHPA’s revitalized leadership will likely intensify collaboration on digital health integration, retail health hubs, and preventive‑care initiatives. As retailers embed pharmacy services and tech firms launch tele‑health solutions, the line between prescription and self‑care blurs, demanding coordinated policy responses. The board’s composition—mixing manufacturers and associate members—positions the association to influence forthcoming regulatory reforms and to champion data‑driven product innovation. Ultimately, CHPA’s governance overhaul aims to sustain industry growth while safeguarding affordable, evidence‑based self‑care options for consumers.